Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more

Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more

Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, is proud... read more

Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is thrilled to announce the activation of multiple premier... read more

Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more

Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

Peabody, MA  – Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug... read more

PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more